Prostate Cancer / 2014 / Article / Tab 3

Clinical Study

Cryotherapy for Primary Treatment of Prostate Cancer: Intermediate Term Results of a Prospective Study from a Single Institution

Table 3

Log Rank test comparative risk.
(a)

RiskAverage
Censored 95% CI
Total numberEvents PercentageEstimateTypical errorLower limitUpper limit

Low2812796.4%120,9263,988113,090128,762
Intermediate3433191.2%112,6436,74299,429125,857
High45172862.2%79,5548,4136,06596,044

Gleason
 5 ( )101100.0%
 6 ( )5445092.6%119,3215,418108,702129,939
 7 ( )1931684.2%112,21710,43491,767132,666
 7 ( )1751270.6%90,50014,37362,329118,671
 8 ( )147750.0%45,0939,79925,88664,299
 9 ( )2200%

Global107218686.4%100,2544,76990,908109,600

(b)

Pairs comparison
Risk123
Chi-squareSig.Chi-squareSig.Chi-squareSig.

Log Rank
(Mantel-Cox)
Low .927.33610,337.001
Intermediate.927.3366,730.009
High10,337.0016,730.009

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.